CD19 Chimeric Antigen Receptor T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19 Chimeric Antigen Receptor T Cells, covering 2024-05-13 to 2024-05-13. Get the full timeline:
Most recent: Clinical Trial Update: Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1]